Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

This UK startup uses AI to treat rare diseases quickly

Editorial team by Editorial team
October 17, 2019
in News, (Crowd)funding, Health & Medtech, Startups
This UK startup uses AI to treat rare diseases quickly
32
SHARES
LinkedInTwitterWhatsAppFacebook

The traditional drug discovery model, which is meant to treat rare diseases takes over a decade and consumes a huge investment. This is where the advancement of technology comes to play and makes it beneficial for patients by coming up with faster, more cost-effective and more efficient treatments.

One such company is Healx, which was founded in 2014 by Dr. Tim Guilliams and Dr. David Brown. The company uses Artificial Intelligence and patient-inspired technology, which makes it specialise in treatments for rare diseases.

- Partner content -
EIT Digital
EIT Digital Challenge 2022 is here!
Calling all European deep-tech scaleups for EIT Digital Challenge 2022Show More
Calling all European deep-tech scaleups for EIT Digital Challenge 2022 Show Less
Read more

Bags €50.5M funding

Cambridge-based Healx just announced that it raised $56 million, which is nearly €50.5 million in a Series B funding round led by one of the largest VC firms in Europe Atomico. Others such as Intel Capital, btov Partners, and Global Brain and existing investors, including Balderton Capital, Amadeus Capital Partners, and Jonathan Milner also participated in the round.

This Series B round follows a $10 million (nearly €9.5 million) Series A round in 2018. Since then, Healx has strengthened its senior executive team and more than doubled overall headcount.

Rare Treatment Accelerator programme on cards

Healx will use this investment to develop its own therapeutic pipeline and launch its global Rare Treatment Accelerator programme. By leveraging AI and combining knowledge, expertise, and information, the company can discover new treatments and make them available at clinics within 24 months. Also, patient communities can apply to join its Rare Treatment Accelerator programme online.

Clinical trials to test numerous treatment options

Previously, Healx validated the innovative model along with Fragile X Research Foundation. For the uninitiated, Fragile X syndrome is a leading genetic cause of autism. Currently, there is no approved treatment to cure this disease. With the collaboration between Healx and FRAXA, the promising clinical trials to test numerous treatment combinations will be launched soon. Later in 2020, clinical programmes for other rare diseases will be started.

Rare disease treatments by 2025

Healx operates with the mission to provide 100 rare disease treatments in the clinics by 2025. It’s AI platform called Healnet delivers data-driven treatment predictions that shorten the discovery-to-clinic time to as little as 24 months. This is the world’s leading AI platform, which works on rare diseases and integrates scientific literature, proprietary data, and clinical trial results with a biomedical knowledge graph.

Main image picture credits: Healx

Stay tuned to Silicon Canals for more European technology news.

Also read,

Meet Hiber, the Amsterdam space tech startup that wants to provide global IoT coverage at a low cost

 - Partner content -
How cybersecurity scaleup Intigriti conquered the world?
How cybersecurity scaleup Intigriti conquered the world?
Catch our interview with Paul Down, Head of Sales at Intigriti.
Catch our interview with Paul Down, Head of Sales at Intigriti. Show Less
Read more
Tags: fundingstartups
Share2Tweet6SendShare18

Partner content | Work with us

Tokenisation is the future of the financial services industry, and Luxembourg’s Tokeny is at the helm of this change

Copilot for growers: Source.ag’s Rien Kamman explains how it helps growers increase their fresh produce with AI

Waste problem is complex, but Seenons has a solution: CEO and co-founder Joost Kamermans explains the plan

Want to scale your business in Germany and Europe? Here’s how the Scaleup Landing Pad Hamburg can help

Is your deep tech scaleup aiming high? The EIT Digital Challenge 2022 can get you there

Silicon Canals | Jobs


Breaking news from Amsterdam | Partner

Amsterdam and Paris-based Trezy bags €1M, opens European headquarters in the Dutch capital

Amsterdam’s Just Eat Takeaway made progress towards profitability in H1 2022: Report

9 Amsterdam-based startups that are cooling the planet

Amsterdam-based CarbonCancel, a company that helped offset carbon footprint, shuts shop: Know more

Advertisement

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy Policy
  • Cookie Policy (UK)
  • Cookie Policy (EU)
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2022 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact

Silicon Canals 2014-2022 | Website: Bright Idiots

Stay updated with the Silicon Canals daily and weekly newsletters.
We promise we won't spam you. You can choose to unsubscribe anytime.
Stay updated with the Silicon Canals daily and weekly newsletters.
We promise we won't spam you. You can choose to unsubscribe anytime.
Silicon Canals
Manage your privacy

To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Statistics

Marketing

Features
Always active

Always active
Manage options Manage services Manage vendors Read more about these purposes
Manage options
{title} {title} {title}
X
X